Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025
Ascendis Pharma (Nasdaq: ASND) will report third quarter 2025 financial results and provide a business update on Wednesday, November 12, 2025 after the U.S. market close. The company will host a conference call and live webcast on November 12, 2025 at 4:30 p.m. Eastern Time (ET) to discuss results.
Investors may access the live webcast or register for the teleconference via the company's Investors & News website at https://investors.ascendispharma.com. A replay of the webcast will be posted on the same site shortly after the event and will remain available for 30 days.
Ascendis Pharma (Nasdaq: ASND) farà riportare risultati finanziari del terzo trimestre 2025 e offrirà un aggiornamento sull'andamento aziendale mercoledì 12 novembre 2025 dopo la chiusura del mercato statunitense. L'azienda ospiterà una conferenza telefonica e una trasmissione in diretta il 12 novembre 2025 alle 16:30 ora orientale (ET) per discutere i risultati.
Gli investitori possono accedere alla trasmissione in diretta o registrarsi per la teleconferenza tramite il sito Investors & News dell'azienda all'indirizzo https://investors.ascendispharma.com. Una replica della trasmissione sarà pubblicata sullo stesso sito subito dopo l'evento e resterà disponibile per 30 giorni.
Ascendis Pharma (Nasdaq: ASND) reportará resultados financieros del tercer trimestre de 2025 y proporcionará una actualización del negocio el miércoles 12 de noviembre de 2025 después del cierre del mercado de EE. UU. La empresa realizará una llamada de conferencia y transmisión en vivo el 12 de noviembre de 2025 a las 4:30 p.m. hora del Este (ET) para discutir los resultados.
Los inversores pueden acceder a la transmisión en vivo o registrarse para la teleconferencia a través del sitio de Inversores y Noticias de la empresa en https://investors.ascendispharma.com. Una repetición de la transmisión se publicará en el mismo sitio poco después del evento y estará disponible durante 30 días.
Ascendis Pharma (Nasdaq: ASND)은 2025년 3분기 재무 실적을 발표하고 미국 시장 마감 후 사업 현황 업데이트를 제공합니다. 회사는 2025년 11월 12일 수요일에 동시 생중계 및 콘퍼런스 콜을 동부 표준시(ET) 기준 오후 4시 30분에 주최하여 실적을 논의합니다.
투자자들은 회사의 Investors & News 웹사이트 https://investors.ascendispharma.com에서 생방송에 접속하거나 전화회의에 등록할 수 있습니다. 행사 직후 같은 사이트에 생방송 재생이 게시되며 30일 동안 이용 가능합니다.
Ascendis Pharma (Nasdaq: ASND) publiera les résultats financiers du troisième trimestre 2025 et fournira une mise à jour sur les activités le mercredi 12 novembre 2025 après la clôture du marché américain. L'entreprise organisera une conférence téléphonique et une diffusion en direct le 12 novembre 2025 à 16 h 30, heure de l’Est (ET) pour discuter des résultats.
Les investisseurs pourront accéder à la diffusion en direct ou s’inscrire à la conférence téléphonique via le site Investors & News de l'entreprise à l'adresse https://investors.ascendispharma.com. Une rediffusion de la diffusion sera publiée sur le même site peu après l'événement et sera disponible pendant 30 jours.
Ascendis Pharma (Nasdaq: ASND) wird die Finanzergebnisse des dritten Quartals 2025 berichten und ein Update zum Geschäft am Mittwoch, dem 12. November 2025 nach Schluss des US-Marktes geben. Das Unternehmen wird am 12. November 2025 um 16:30 Uhr Eastern Time (ET) eine Telefonkonferenz und Live-Webcast abhalten, um die Ergebnisse zu besprechen.
Investoren können den Live-Webcast auf der Website des Unternehmens Investors & News unter https://investors.ascendispharma.com aufrufen oder sich für die Telekonferenz registrieren. Eine Wiederholung des Webcasts wird kurz nach der Veranstaltung auf derselben Website verfügbar sein und für 30 Tage abrufbar bleiben.
Ascendis Pharma (ناسداك: ASND) ستعلن النتائج المالية للربع الثالث من 2025 وستقدم تحديثاً عن الأعمال في الأربعاء 12 نوفمبر 2025 بعد إغلاق السوق الأمريكية. ستُقيم الشركة مكالمة مؤتمر وبثاً مباشراً في 12 نوفمبر 2025 الساعة 4:30 مساءً بتوقيت شرق الولايات المتحدة (ET) لمناقشة النتائج.
يمكن للمستثمرين الوصول إلى البث المباشر أو التسجيل في المؤتمر عبر موقع الشركة للمستثمرين والأخبار على العنوان https://investors.ascendispharma.com. ستُنشَر إعادة البث على نفس الموقع مباشرةً بعد الحدث وستظل متاحة لمدة 30 يوماً.
- None.
- None.
COPENHAGEN, Denmark, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report third quarter 2025 financial results and provide a business update on Wednesday, November 12, 2025, after the close of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on November 12, 2025, at 4:30 p.m. Eastern Time (ET) to discuss its third quarter 2025 financial results.
Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com. A replay of the webcast will be available on this section of the Ascendis Pharma website shortly after the conclusion of the event for 30 days.
About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ plan to report financial results, provide a business update and host a conference call and live webcast on a certain date, (ii) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients and (iii) Ascendis’ application of TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis’ products and product candidates; unforeseen safety or efficacy results in Ascendis’ development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis’ development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 12, 2025, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, and TransCon are trademarks owned by the Ascendis Pharma group. © November 2025 Ascendis Pharma A/S.
| Investor Contacts: Chad Fugere Ascendis Pharma ir@ascendispharma.com Patti Bank ICR Healthcare +1 (415) 513-1284 patti.bank@icrhealthcare.com | Media Contact: Melinda Baker Ascendis Pharma media@ascendispharma.com |
FAQ
When will Ascendis Pharma (ASND) report third quarter 2025 results?
What time is the Ascendis Pharma (ASND) conference call and webcast on November 12, 2025?
How can investors access the Ascendis Pharma (ASND) live webcast for Q3 2025?
Will a replay of the Ascendis Pharma (ASND) Q3 2025 webcast be available?
Where will Ascendis Pharma (ASND) post presentation materials and the webcast link for the Q3 2025 update?
Do investors need to register to join Ascendis Pharma's (ASND) teleconference for Q3 2025?
